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PHYSICIAN BELIEFS ABOUT INSULIN PENS VERSUS VIALS, THERAPY CHOICE
FACTORS, AND PATIENT CHARACTERISTICS AMONG ELDERLY TYPE 2
DIABETES PATIENTS
Eby E1, Frois C2, Guerin A3, Boggs JA1, Nyhuis A1, Swindle R1
1Eli Lilly and Company, Indianapolis, IN, USA, 2Analysis Group, Inc., Boston, MA, USA,
3Analysis Group, Ltee., Montreal, QC, Canada
OBJECTIVES: To assess physician beliefs on the relative benefits of pens vs. vials,
prescribing drivers, and characteristics of patients newly initiated on basal insulin
analog via pens vs. vials among elderly type 2 diabetes patients. METHODS: An
online survey of 352 U.S. primary care physicians was used to collect retrospective
patient chart data on 500 elderly type 2 diabetes patients who initiated on basal
insulin analog in 2009. For each physician, patient chart selection was randomized
among eligible patients. Data on physician characteristics, physicians’ opinion on
the impact of different routes of administration (ROA), main drivers for selecting a
particular ROA for each patient, and patient characteristics were collected.
RESULTS: The majority of physician respondents were part of a group practice
(77.8%) and treated a mean of 235.5 (SD185.0) type 2 patients  65 years old in
2009. Patient characteristics were similar in terms of age and diabetes duration.
However, significantly more Caucasians (p  0.011) and patients covered by Medi-
care only (p0.015) were initiated on pens, whereas significantly more women
(p0.003), Black/African Americans (p0.011), and dual eligible patients (Medicare
Medicaid; p0.008) were initiated on vials. Patients initiated on vials had higher
median baseline HbA1c values (8.7 vs. 8.4, p0.001).Survey findings suggested that
physicians prescribed vials primarily due to patients’ economic constraints (62.9%
of vial users vs. only 2.4% for pen users), although a majority of physicians consid-
ered pens better than vials (89.2% in terms of adherence, 65.1% in terms of HbA1c
control, and 55.4% in terms of resource utilization). CONCLUSIONS: Results from
this retrospective chart extraction survey suggest that patient characteristics dif-
fered between patients initiated on pens vs. vials, and that despite insulin pens
being perceived as having better outcomes by physicians, economic considerations
play a dominant role in the choice of insulin vials.
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DIFFUSION OF NEW TECHNOLOGIES POST REIMBURSEMENT – MONITORING
THE USE OF LIRAGLUTIDE IN PRIMARY CARE
O’Leary A1, Usher C1, Mulhall C1, Barry M2
1National Centre for Pharmacoeconomics, Dublin 8, Ireland, 2St. James’s Hospital, Dublin,
Ireland, Ireland
OBJECTIVES: Liraglutide, a GLP-1 receptor agonist used to treat Type 2 diabetes
patients, is reimbursed in Ireland since November 2009. Budget impact analysis at
this time assumed use of the 1.2mg dose in 95% of patients. A 1.8mg maintenance
dose is also available. The aim of this study was to examine utilisation of liraglutide
in the post reimbursement ‘real world’ setting. METHODS: Data were analysed
using a national prescription claims database from November 2009 to December
2011. Numbers of patients receiving prescriptions for liraglutide and exenatide
were calculated per month and the average number of pens dispensed per pre-
scription and duration of use was analysed for liraglutide. Drugs were classified
and identified according to the WHO ATC classification system. Analysis was per-
formed in SAS (v9.1). RESULTS: The number of prescriptions for liraglutide in-
creased from 0.3 to 0.9/1000 GMS population over the study period. The number of
exenatide prescriptions decreased from 0.3 to 0.15/1000 GMS population. Fifty per-
cent of patients dispensed liraglutide in 2010 and 2011 received 1.8mg per prescrip-
tion. The average duration of use of liraglutide ranged from  3 months (41% of
patients),  6 months (26% of patients),  9 months (18% of patients) and  12
months (15% of patients). There was no correlation between the average duration
of use and number of pens dispensed per prescription (Pearson correlation coeffi-
cient -0.05). CONCLUSIONS: Results from the study indicate that the higher daily
dose (1.8mg) of liraglutide is used in ‘real world’ setting compared to pre-reim-
bursement assumptions. There are opportunity costs and clinical outcome impli-
cations arising from using the higher dose of liraglutide, given that there is no
robust evidence of additional benefits on glycaemic control from the higher dose.
This analysis highlights the role that monitoring can play in informing pharmaco-
economic evaluations and guideline recommendations post reimbursement.
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CHARACTERISTICS OF LONG-ACTING SOMATOSTATIN (SSA) USE IN
ACROMEGALY IN THE NETHERLANDS
Bezemer ID1, Penning FJA1, Brulais S2, Verduyn CSC3, Herings RMC1
1PHARMO Institute for Drug Outcomes Research, Utrecht, The Netherlands, 2Ipsen pharma,
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OBJECTIVES: To compare the potential cost of long-acting treatment with lan-
reotide vs octreotide for acromegaly using patient treatment characteristics from
the PHARMO Record Linkage System (RLS) in the Netherlands. METHODS: A cost
minimization model was used to compare the lifetime costs of the SSAs. Data for
patients receiving outpatient dispensing of long-acting SSA (2003–2010) were se-
lected from the PHARMO RLS. Acromegalic patients were identified by hospital
discharge diagnoses and were stratified by first SSA dispensed during the study
period. Dosing and injection intervals were assessed during stable treatment peri-
ods (i.e., the period of SSA dispensings with constant dosage and little variation in
injection intervals). RESULTS: Sixty-two octreotide LAR users and 16 lanreotide
Autogel users were identified. Stable treatment was observed in 46/62 (74%) oc-
treotide users and 12/16 (75%) lanreotide users. The median (IQR) duration of the
first stable phase was 3 (2-9) months for octreotide and 2 (1-3) months for lan-
reotide. During treatment stability, mean (SD) injection intervals were 28 (10)
for octreotide and 30 (6) for lanreotide; however, when patients were categorized
into weekly intervals, there were more users on shorter intervals with octreotide
than lanreotide (15/46 [33%] vs 2/12 [17%] injected every 3 weeks or more frequently
and 9/46 [19%] vs 3/12 [25%] injected every 5 weeks or less frequently respectively).
Based on similar dosing but longer injection intervals for lanreotide users, there
appeared to be a 5% lower average cost per acromegalic patient treated with lan-
reotide over octreotide. CONCLUSIONS: The longer injection interval observed
with the high dose lanreotide under stable long-acting SSA treatment resulted in
reduced costs compared to octreotide. However, the patient numbers of this rare
disease and the limited period of treatment stability limit the power to detect
differences between preparations.
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PATIENT ACCESS, HBA1C KNOWLEDGE, AND HEALTH OUTCOMES AMONG
TYPE 2 DIABETES PATIENTS IN BRAZIL
Annunziata K1, Pomerantz D1, Dibonaventura MD2, Follador W3
1Kantar Health, Princeton, NJ, USA, 2Kantar Health, New York, NY, USA, 3Sanofi, São Paulo ,
São Paulo , Brazil
OBJECTIVES:Although the primary goal among patients with type 2 diabetes (T2D)
is gylcemic control, lack of patient education and health care access may represent
a major obstacle to proper disease management, particularly in emerging markets
such as Brazil. The aim of the current study was to document the level of patient
knowledge of HbA1c levels and its effect on health outcomes. METHODS: Data
were analyzed from the Brazil 2011 National Health and Wellness Survey, a cross-
sectional health survey of adults in Brazil (N12,000). Demographics (age, gender,
education, socioeconomic status, insurance type), health history (HbA1c level, FPG
level, frequency of testing), and health outcomes (health status using the SF-12v2,
work productivity loss using the WPAI, and health care resource use) were assessed
for all respondents. RESULTS: A total of 480 respondents (4.0%) reported a diagno-
sis of T2D of whom 85.38% did not know their level of HbA1c. Among those who
were aware of their HbA1c level, 60.34% reported being uncontrolled (i.e., a level
greater than 7%). Patients who were uncontrolled reported significantly worse
physical health status (39.43 vs. 46.68) and a significantly greater percentage work
overall impairment (42.93% vs. 25.58%) compared with those who were controlled
(all p.05). Access to care also was associated with better outcomes as those with
private insurance were significantly more likely to have an HbA1c test in the past 3
months (15.57% vs. 6.57%) and significantly less likely to have never been tested
(38.32% vs. 43.01%) than those with just public insurance (all p.05).
CONCLUSIONS: The lack of awareness of HbA1c levels suggests a significant gap in
patient education. Given the high probability of being uncontrolled, this lack of
patient education may have significant humanistic and economic consequences
for Brazil from a societal perspective. Improvement in access and education may
help improve overall T2D management.
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MAIN FACTORS ASSOCIATED TO COSTS OF TYPE 2 DIABETES MELLITUS (DM2)
CARE IN SPAIN. A SYSTEMATIC REVIEW OF THE 2001-2011 LITERATURE
Gonzales segura D1, Paz S2, Lizan L2
1Almirall, Barcelona, Barcelona, Spain, 2Outcomes 10, Castellon, Castellon, Spain
OBJECTIVES: Type 2 diabetes mellitus (DM2) patients are at long-term risk of car-
diovascular events and of microvascular complications that contribute to the bur-
den of the disease. The objective is to identify the main factors directly associated
to costs of DM2 care in Spain. METHODS: A systematic review of cost of disease
studies published in English or Spanish between January 2001 and December 2011.
A search of electronic databases [international and national] and hand search of
reference lists of key publications was performed. A methodological quality assess-
ment of reviewed publications applying the Center for Evidence Based Medicine
(CEBM, 2012) tool was performed. All costs updated to €, 2011. RESULTS: A total of
1505 articles were identified, 639 were excluded and 28 were retrieved. Total na-
tional health care expenditure intended for DM2 care in Spain was about €2,800
million per year. Direct costs varied between €851.23 and €4,882.80 per patient/year.
Main cost drivers were: other pharmacological treatments different from antidia-
betics (37.83%), hospital admissions (31.93%), medical visits (25.57%), and oral an-
tidiabetics (4.67%). Severe and moderate hypoglycemias increased costs 174 and 8
times, respectively, compared to those episodes with no need of medical care. DM2
costs increased by 59.5% if the goal of HbA1c7% was not reached; by 30% with
obesity, and by 64.5% if disease related complications appeared. Each 10% raise in
adherence to oral antidiabetic treatment represented a 2% to 4% reduction in DM2
costs. Levels of CEBM recommendation were 2c (16 studies), 3b (8 studies) and 4 (4
studies). CONCLUSIONS: Main factors directly associated to costs of DM2 care in
Spain were hypoglycemia, DM2 related complications, HbA1c control, obesity and
treatment adherence. Strategies aimed to improve these factors would have a
major impact on costs reduction.
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OBESITY AND FREQUENT HYPOGLYCEMIA IN EUROPEAN TYPE 2 DIABETES
PATIENTS
Vietri J1, Isherwood G2, Le pautremat V3, Eschwège EM4
1Kantar Health, Princeton, NJ, USA, 2Kantar Health, Epsom, Surrey, UK, 3Kantar Health,
Montrouge, France, 4INSERM, Villejuif, France
OBJECTIVES: To examine the association between obesity and hypoglycemia in
adults with type 2 diabetes (T2D), and assess whether hypoglycemic events (‘hy-
pos’) and obesity are related to health care use among these patients in France,
Germany, and the UK. METHODS: Data from the 2011 5EU National Health and
Wellness Survey were used (n57,512). All data were self-reported. T2D patients
were grouped according to frequency of hypos requiring assistance from others
(moderate/severe hypoglycemia); those reporting moderate/severe hypos at least
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twice per year were considered to have frequent hypos. Logistic regression was
used to evaluate the link between obesity and frequent hypos, controlling for age,
gender, country, and insulin use. Generalized linear models quantified the rela-
tionship between health care use and patient characteristics, including obesity,
frequent hypos, and insulin use. RESULTS: Height and weight data were available
for 2,780 T2D patients in France, Germany, and the UK. Obesity was more common
among patients in Germany (51.0%) and the UK (53.4%) than France (43.9%, both
p.05); frequent hypos were more common in France (16.5%) and the UK (13.2%)
than Germany (8.2%, both p.05). Overall, patients with frequent hypos were more
likely to be obese (57.6% vs. 49.1%, p.01), female (40.6% vs. 32.7%, p.01), insulin
users (36.7% vs. 17.5%, p.001), and have HbA1c 7.0% (61.3% vs. 49.4% of those
reporting HbA1c, p.01) than other patients. Obesity and frequent hypos were
associated after adjusting for covariates (OR 1.27, p.05). Multivariable models of
health care use showed frequent hypos were associated with more physician and
ER visits, and obesity was associated with more physician visits and hospitaliza-
tions (all p.05). CONCLUSIONS:Obese patients are at increased risk for moderate/
severe hypoglycemia, and both obesity and hypoglycemic events are associated
with more health care use. Improving management of obesity among T2D patients
may reduce the impact of diabetes on health care systems in Europe.
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EFFECTIVE HEALTH CARE BUDGET PLANNING FOR INNOVATIVE DRUGS IN
DIABETES TREATMENT IN TURKEY; FROM THE PERSPECTIVE OF THE SOCIAL
SECURITY INSTITUTION (SSI)
Kececioglu S, Ulus P, Cukadar F
Boehringer Ingelheim Turkey, ISTANBUL, TURKEY, Turkey
OBJECTIVES: Diabetes therapies constitute one of the highest budgets allocated by
the Social Security Institution (SSI) each year in Turkey (within top 15). However, a
standard budget allocation plan for reimbursement of innovative drugs in diabetes
does not exist in Turkey. This study aims to offer a perspective for effective health
care budget planning for innovative drugs in diabetes for the SSI in order to achieve
patient access. METHODS: Total budget spent by SSI for diabetes treatment is
analyzed for the last three years. All treatment groups are defined for % unit and
Turkish Lira (TL) growth and those values are investigated relative to the total
diabetes budget. The current budget allocation structure for innovative drugs is
defined and a new methodology is offered. RESULTS: The highest budget in diabe-
tes is allocated for human insulin analogues with a total spending of 949,278,748 TL
(45.7%), followed by glitazones 388,374,291 TL (18.7%) and sulphonylurea
244,190,634 TL (11.8%). However, the total budget allocated for innovative drugs as
DPP-4 inhibitors and GLP-1 agonists is around 4.2%. The following steps for forward
planning of budgets are proposed: Analysis of each treatment option within the
same group with respect to effectiveness; defining reimbursement conditions
(price-volume) for each option based on effectiveness; analysis of each treatment
group with respect to effectiveness; defining budget allocated for each treatment
group based on effectiveness; biannual review of the budget realizations.
CONCLUSIONS: Re-evaluation of current therapies in terms of budget contribu-
tions and effectiveness may identify savings in SSI budget that could be freed up for
new treatment options becoming available. A stepwise approach including the
reevaluation of existing treatments in diabetes would be necessary in Turkey.
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ASSOCIATION BETWEEN HYPOGLYCAEMIC EVENTS AND SHORT-TERM
DISABILITY AMONG PATIENTS WITH DIABETES BEING TREATED WITH
INSULIN USING A CLAIMS DATABASE APPROACH
Young T1, Shao W2, Weng W1, Bouchard JR2
1Novo Nordisk Inc, Princeton, NJ, USA, 2Novo Nordisk, Inc., Princeton, NJ, USA
OBJECTIVES: To evaluate the association between hypoglycaemic events (HEs) and
short-term disability (STD) using a retrospective case-control design among pa-
tients with diabetes receiving insulin therapy within a claims database.METHODS:
U.S. medical claims data was obtained from Thomson Reuters MarketScan Com-
mercial, Medicaid, and Health and Productivity Management databases from 1
January 2007 to 31 December 2009. Patients were selected if they were enrolled in a
health plan, eligible for STD for 12 months from the first date of an anti-diabetic
drug claim (index start date), and had 1 insulin claim. Analysis was performed
comparing patients who had at least 1 HE claim entered to those who had none.
HEs were defined based on ICD-9CM codes: 250.8, 251.0, 251.1, or 251.2 and probably
were serious/significant events entered on behalf of the patient. STD was mea-
sured by a binary indicator, number of cases, and total days absent from work. The
relationship between HEs and STD was evaluated before and after adjusting for
covariates. Regression models were used to adjust for known influential covariates
(duration of index period and Charlson Comorbidity Index) and fixed effects (sex,
age group, region, health plan type, employment status, diabetes type, prescription
regimen, and diabetic complications). RESULTS: There were 15,020 patients who
met the inclusion criteria with a mean index period of 2.4 years. 478 (3.2%) had
experienced 1 HEs and 3893 (25.9%) 1 STDs. The odds of having 1 STDs for
those with1 HEs was 74.7% higher than those with no HE (Adjusted OR: 1.747; 95%
CI: 1.429, 2.135). Patients reporting HEs had an average of 3.24 more days of absence
from work per year due to STDs than patients without HEs after adjusting for the
covariates. CONCLUSIONS: Results indicate a significant association between expe-
riencing HEs and the occurrence of STD among patients receiving insulin therapy.
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CLINICAL EFFECTIVENESS OF INCREASED PHYSICAL ACTIVITY IN TYPE 2
DIABETES, SYSTEMATIC REVIEW
Herrmann KH1, Semlitsch T2, Jeitler K3, Schuermann C1, Janzen T1, Hemkens LG4,
Matyas E2, Pignitter N2, Siebenhofer-kroitzsch A5, Horvath K6
1IQWiG, Cologne, Germany, 2EBM Review Center, Graz, Austria, 3EBM Review Center, Graz ,
Austria, 4Stanford University, Stanford, CA, USA, 5Goethe-Universität Frankfurt am Main
Zentrum für Gesundheitswissenschaften, Frankfurt am Main, Germany, 6EBM Review Center,
Graz, Germany
OBJECTIVES: To investigate the clinical effectiveness of increased physical activity
within adults with type 2 diabetes. METHODS: A systematic review was under-
taken to identify relevant randomized controlled trials (RCTs). MEDLINE, EMBASE
and the Cochrane databases were searched for RCTs up to December 2010 as well as
for systematic reviews to identify further RCTs. Reference lists were screened. For
inclusion into the review, studies had to compare increased physical activity to no
such an intervention with a follow-up period of at least 24 weeks. Patient-relevant
outcomes were predefined: all-cause mortality, cardiovascular morbidity and mor-
tality, health-related quality of life (HRQoL), end-stage renal disease, amputation,
retinal damages, hypoglycemia and adverse events. The risk of bias of each indi-
vidual study was assessed. RESULTS: Eight RCTs met the inclusion criteria and
reported on predefined outcomes. The following interventions were compared to
no such an intervention: endurance-training/strength-training or sessions with
mixed (aerobic and resistance) training. The studies included 1202 patients with a
mean age of 60 years. Only for the endpoints HRQoL and adverse events properly
reported results were found: 4 studies analyzed HRQoL but all used different out-
come measures, only one of the studies reported a statistically significant effect. 6
studies presented data on adverse events, 4 of them incompletely, 2 of them show-
ing no significant treatment effect CONCLUSIONS: Although there is a vast body of
literature on physical activity in adults with type 2 diabetes only 8 studies met the
inclusion criteria. Evidence on patient-relevant endpoints was scarce, as most
studies focused on HbA1c as their primary endpoint. We found no effect of in-
creased physical activity on HRQoL and adverse events in patients with type 2
diabetes. Conclusions for other endpoints could not be drawn. Thus, there is a great
demand for further studies with patient relevant primary endpoints.
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CHARACTERISTICS OF PATIENTS WITH DIABETES IN SOUTHWESTERN
ONTARIO, CANADA
Petrella RJ1, Tarride JE2, O’Reilly D3, Xie F2, Goeree R2
1Lawson Health Research Institute, London, ON, Canada, 2McMaster University, Hamilton, ON,
Canada, 3PATH Research Institute, McMaster University, Hamilton, ON, Canada
OBJECTIVES: Although Canada is reputed to be an international leader in diabetes
surveillance, there are gaps in knowledge about effectiveness of management,
resource utilization and health outcomes of people being treated for diabetes. The
objectives of this study were to follow a cohort of newly diagnosed persons with
diabetes in South-Western Ontario (SWO) over a 5-year period to document epide-
miology, management, baseline characteristics, clinical outcomes and resource
utilization. METHODS: Data from this cohort were compared to an age and gender
matched control group of individuals without diabetes. Regression analyses were
conducted to evaluate the impact of anti-diabetic medications on glycemic levels
and control after adjustment for age, gender and baseline HbA1c. RESULTS: A total
of 3861 individuals with newly diagnosed diabetes in 2002 were identified. The
mean HbA1c levels increased from 7.4% at time of diagnosis to 8.21% at the end of
the study in 2008. A similar trend was observed for fasting glucose levels (6.71% at
baseline to 7.41% in 2008). After controlling for covariates, regression analysis re-
sults indicates that continuous and intermittent use of anti-diabetic drugs com-
pared to no drug use had no significant impact on 2-year HbA1c levels. Further, the
results of our study indicate that a large proportion of the cases had uncontrolled
hypertension and hyperlipidemia. An interesting finding is that the average num-
ber of physician visits decreased from 7.9 per year at baseline to 4.8 at the end of 5
years in cases, whereas in controls, physician visits increased from an average of
6.8 at baseline to 7.4 five years later. Hospitalizations decreased over time from an
average of 6 days at baseline, to 2.4 days at the end of 5 years. CONCLUSIONS:
Consistent with other studies, these findings suggest that a minority of people with
diabetes in South-Western Ontario achieved optimal glycemic control.
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DETERMINANTS OF TREATMENT CHANGES OF ORAL ANTI/DIABETIC DRUGS IN
THE UK
Maguire A1, Mitchell B2
1United BioSource Corporation, London, UK, 2Eli Lilly and Company, Indianapolis, IN, USA
OBJECTIVES: In the UK, Oral Anti-Diabetic drugs “OAD” are administered to control
hyperglycaemia in type 2 diabetes when HbA1c exceeds 48mmol/mol. Guidelines
are designed to improve HbA1c response through regimen change. The aim is to
examine factors associated, especially HbA1c, with treatment regimen change in
clinical practice. METHODS: All patients who initiated an OAD (except rosiglita-
zone) in the GPRD database between 1/1/2006 and 25/2/2011 were included. HbA1c
was assigned to baseline and to each year following OAD initiation. The median
HbA1c is hereby reported using the mmol/mol scale. Each patient was classified as
augmenter, switcher, discontinuer or control (no change). This status was updated
at each year since OAD initiation; multinomial logistic regression models were
used to assess factors associated with treatment change; the odds ratios “OR” (with
95% confidence interval) represent the relative likelihood of change versus no
change.RESULTS:Of 63060 patients 34737 had HbA1c recorded around 1 year since OAD
initiation. HbA1c at one year was associated with treatment changes at the same time,
beinghighest foraugmentationwith insulin (80mmol/mol), augmentationwithOAD(68),
switching (63) and lowest for discontinuation and controls (both 51). Similar results were
seen at subsequent years. At one year since OAD initiation, the adjusted regression model
confirmed the increased HbA1c and chance of augmentation (OR2.8 per 10mmol/mol
increase; 2.7-2.9), switch (OR2.4; 2.2-2.5) and discontinuation (OR1.1; 1.1-1.2). Baseline
use of gliclazide was also associated with increased augmentation (OR1.6; 1.3-2.0),
A507V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) A 2 7 7 – A 5 7 5
